BioAge Labs announces additional interim data from Phase 1 trial of BGE-102

BioAge Labs (BIOA) announced additional positive interim data from the ongoing Phase 1 clinical trial evaluating BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor being developed for the treatment of patients with cardiovascular risk factors. In a multiple ascending dose, MAD, cohort of participants with obesity and elevated baseline inflammation, BGE-102 120 mg once daily achieved an 86% median reduction in high-sensitivity C-reactive protein at Day 14. Notably, 93% of BGE-102-dosed participants achieved hsCRP levels below 2 mg/L-the clinically recognized threshold for reduced cardiovascular risk. These findings build on positive interim data announced in December 2025 from SAD and initial MAD cohorts, which demonstrated that BGE-102 was well tolerated, achieved dose-proportional pharmacokinetics supporting once-daily dosing, and produced 90-98% suppression of IL-1beta at Day 14 trough. Those data also confirmed high brain penetration, with cerebrospinal fluid concentrations exceeding the IC90 at doses of 60 mg and above.